Work

A phase II study to evaluate the safety and efficacy of OQL011 on VEGFR inhibitor-associated hand-foot-skin reaction in cancer patients.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps12132

Authors: Mario E. Lacouture, Milan J. Anadkat, Omkar Subhash Marathe, Nicholas J. Vogelzang, Elaine Tat Lam, Benjamin Kaffenberger, Jennifer N. Choi, Mark L. Webb, Robert Claude Tyler, Juegang Ju, Hong Tang, Jie Luo, Anisha Patel

Institutions: Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Oncology Institute of Hope and Innovation, Comprehensive Cancer Centers of Nevada, University of Colorado Cancer Center, University of Colorado Anschutz, The Ohio State University Wexner Medical Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3173109909

Cites:

Cited by:

Related to: 10